ATHA.Athira Pharma, INC

4/A: Athira Pharma SVP, Finance and Accounting, Robert Renninger, Corrects Stock Option Vesting Schedule in Amended SEC Filing

Sentiment:

SEC Filing

📋All filings for Athira Pharma, INC
🔒Login to Follow

Robert Renninger, SVP of Finance and Accounting at Athira Pharma, files an amended SEC Form 4 to correct the vesting schedule of a previously reported stock option award.

Summary

  • Robert Renninger, SVP of Finance and Accounting at Athira Pharma, filed an amended SEC Form 4/A on March 12, 2025.
  • The amendment corrects an error in the vesting schedule of a stock option award previously reported in the original Form 4 filed on March 4, 2025.
  • The stock option, granted on March 3, 2025, allows Renninger to buy 73,350 shares of Athira Pharma's common stock at an exercise price of $0.3762 per share.
  • One-fourth of the shares are scheduled to vest on the one-year anniversary of the grant date, and one thirty-sixth of the remaining shares vest monthly thereafter, contingent upon continued service as a Service Provider.

Sentiment

Score: 7

Explanation: The document is a routine correction of a regulatory filing, indicating standard corporate governance practices. The sentiment is neutral to slightly positive as it reflects attention to detail and compliance.

Industry Context

This filing is a routine disclosure related to executive compensation and stock options, common in the pharmaceutical industry.

Key Dates

DateDescription
03/03/2025Date of stock option grant
03/04/2025Date of original Form 4 filing with incorrect vesting schedule
03/12/2025Date of amended Form 4/A filing to correct vesting schedule
03/02/2035Expiration date of the stock option

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.